Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial

Hideka Inoue, Hiroshi Maegawa, Satoshi Ugi et al.|Journal of Diabetes Investigation|2018

Cited by 62